Escient Pharmaceuticals has grabbed a meaty $77.5 million series B with the help of Sanofi’s VC arm as the biotech also starts its first in-human tests.
The San Diego biotech came onto the scene back in 2018 with $40 million in series A funding to develop novel G protein-coupled receptor-targeted drugs for a wide range of indications. The startup's first focus was on neuro-immuno-inflammatory and autoreactive diseases.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,